Oncologists in the EVES discuss new treatments for kidney cancer.

– in Valencia about 300 new cases occur each year

, advances in molecular biology allow know certain mechanisms involved in the development of renal tumors

Valencia, 2011-September EVES (Valencian School of health studies) has organized a seminar on oncology that involved a group of specialists in this discipline that have dealt with issues surrounding renal cancersuch as the situation of the disease, progress on diagnosis and new existing pharmacological treatments.

The director of the EVES, Joaquín Ibarra, has pointed out in his inaugural speech to the day aims to discuss the biological, epidemiological and clinical aspects of renal cancer with different available treatments, the studies that are supported, their mechanisms of action, efficacy and toxicity ”.

Currently, Spain kidney cancer incidence varies from a regions to others, but on the whole is approximately 10 cases per every 100,000 men and 4 for every 100,000 females, which represents about 3,000 new cases a year in total and more than 300 only in Valencia.

The incidence of this type of tumor is increasing in the past 30 years, in part by the generalization of the abdominal diagnostic tests that determine the incidental tumor diagnosis, as well as environmental factors such as pollution, tobacco , points out Dr. Miguel Angel Climent, of the IVO Hospital of Valencia and Vocal of the group Spanish of Genitourinaria Oncology (SOGUG).

Renal cancer corresponds to 3% of all diagnosed cancers and 2% of mortality from cancer, adds Dr. Climent.

The patient who suffers kidney cancer is typically a person in the sixth or seventh decade of life, more often male, and smoking, but it is not uncommon to see people with a completely different profile, as for example a woman in the fourth decade of life and non-smoker ”, says Dr. Gaspar Reynés, oncologist of University Hospital and Polytechnic La Fe of Valencia. Has no doubt changed is that in recent years are diagnosed more patients in early stages of the disease, partly by finds casual to perform a test of image or an analysis otherwise ”, according to the expert.

In his healing, the probability is closely tied to the spread of the disease at the time of diagnosis, so in the case of small tumors confined to the own kidney 5-year survival is more than 90 %, while those scattered at a distance, the 5-year survival is less than 10%; In addition, other factors play forecasts both clinical and biological, according to Dr. Reynés. globally, the 5-year survival has improved in the last half a century, from 40% to 65% approximately ”, has added the specialist.

New treatments

On this day, framed in the discussion forums organized by EVES on current health issues, and which are directed generally to specialists in different health areas, experts have also featured new treatments in this type of cancer.

Thus, in the opinion of Dr. Mariló Torregrosa, oncologist of the Hospital Lluís Alcanyís in Xàtiva, the treatment of renal tumors has undergone an important change in recent years ”. Thanks to advances in molecular biology ”, has been added, know some of the mechanisms involved in the development of renal tumors; block them, through mechanisms of action different chemotherapy drugs, has managed to prolong survival in this pathology ”.

Torregrosa had concluded that in the not distant future can individualize treatments, modifying the natural history of the disease ”.

Dr. Isabel Chirivella, oncologist of Hospital Clínico Universitario de Valencia, has indicated that in recent years have developed new drugs that have changed radically treatment of metastases of this tumor, achieving an improvement in the quality of life of these people and an increase in survival ”.

GSK Oncology

GSK’s global research in Oncology includes collaborations with more than 160 cancer centers. GSK is fighting cancer from all angles with a new generation of cancer therapies focused on the patient for the prevention, palliative care, chemotherapy and targeted therapies.